Find a trial

Our clinical trials database will help you look for a clinical trial that might be suitable for you. We hope this helps you to make informed decisions and choices about your lymphoma treatment and care. 

Questions about Lymphoma TrialsLink and how to use it? Read more about Lymphoma TrialsLink here or if you have a general question about clinical trials in the UK or Lymphoma TrialsLink, please contact us at trialslink@lymphoma-action.org.uk.

Note: We are not able to refer people to specific trials. If you’re interested in taking part in a trial you have found on Lymphoma TrialsLink, we recommend that you print the trial summary and discuss it with your consultant. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.

Trial name Closing date

OASIS II: A phase 2 trial of potential treatment regimens in people with mantle cell lymphoma

MK-4280A-008: A phase 3 trial of favezelimab/pembrolizumab compared to chemotherapy in relapsed or refractory classical Hodgkin lymphoma

Determine trial treatment arm 1: A phase 2/3 trial of alectinib in people with ALK positive lymphomas

STATIC: A study comparing intermittent and continuous treatment with ibrutinib in CLL/SLL

Zuma-22: A trial testing axicabtagene ciloleucel in people with relapsed or refractory follicular lymphoma

EBV: A phase 2 trial of tabelecleucel in people with Epstein-Barr virus associated diseases

CELESTIMO: A study testing the efficacy and safety of either mosunetuzumab or rituximab with lenalidomide in adults with relapsed or refractory follicular lymphoma after one line of systemic therapy

OptiMATe: A phase 3 trial to optimise the MATRix chemotherapy regimen in primary central nervous system lymphoma

BRUIN-CLL-314: A phase 3 trial of pirtobrutinib compared to ibrutinib in adults with chronic lymphocytic leukaemia

TRANSCEND FL: a phase 2 trial of JCAR017 in relapsed or refractory low-grade B-cell non-Hodgkin lymphoma

ALLELE: A phase 3 trial of a targeted treatment called tabelecleucel in people with post-transplant lymphoproliferative disorder

RADAR: A phase 3 trial of an antibody treatment called brentuximab vedotin in people with early stage Hodgkin lymphoma

KEYNOTE 667: A phase 2 trial of pembrolizumab with chemotherapy in children and young adults with classical Hodgkin lymphoma

BRUIN CLL-322: A randomised, phase 3 study of pirtobrutinib plus venetoclax and rituximab compared to venetoclax plus rituximab in previously treated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL)

MOGAT: A phase 2 trial of mogamulizumab in cutaneous T-cell lymphoma

SYMPHONY-1: a phase 1b/3 double-blind, randomised study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma

Mangrove: A phase 3 trial of zanubrutinib plus rituximab in older people with untreated mantle cell lymphoma

STP938: A phase 1/2 study of STP938 for adults with relapsed or refractory B-cell and T-cell lymphomas

ELM-2: a phase 2 trial assessing the safety of odronextamab in adults with relapsed or refractory B-cell non-Hodgkin lymphoma

ELM-1: a phase 1 trial of odronextamab in people with B-cell non-Hodgkin lymphoma or CLL

AZD7789: A phase 1/2 trial of AZD7789 in people with relapsed or refractory classical Hodgkin lymphoma

Pola-R-ICE: A phase 3 trial of combining standard R-ICE chemotherapy with polatuzumab in people with diffuse large B cell lymphoma (DLBCL)

BGB-11417: A phase 1 trial of BGB-11417 in people with B cell malignancies

MoTD: A phase 2 trial comparing interventions for the prevention of graft versus host disease after unrelated donor stem cell transplantation.

CLOVER-1 and CLOVER-WaM: A phase 2 trial looking at the medication iopofosine I 131 (CLR 131) in people with B-cell lymphomas and an expansion in Waldenstrom Macroglobulinaemia (WM)

Mogamulizumab: A phase 2 trial evaluating the safety of mogamulizumab in relapsed or refractory cutaneous T-cell lymphoma

CO43805: A Phase 1b trial of mosunetuzumab or glofitamab in people with B-cell Non-Hodgkin Lymphoma

DTP3: A phase 1/2 trial of DTP3 in people with relapsed or refractory diffuse large B cell lymphoma (DLBCL)

MK1026-003: A phase 2 trial of the medication MK-1026 in blood cancers

LOTIS 7: A phase 1b trial of loncastuximab tesirine in combination with other anti-cancer agents in adults with relapsed or refractory B-cell non-Hodgkin lymphoma

SEA-TGT : A phase 1 trial of SEA-TGT in advanced cancers including lymphoma

CC-99282: A phase 1 trial of CC-99282 alone and in combination with anti-lymphoma agents in people with relapsed or refractory non-Hodgkin lymphoma

ALLCAR19: A phase 1 trial of CAR T-cell therapy in adults with relapsed or refractory DLBCL, CLL, SLL, FL or MCL

BRUIN CLL-313: a phase 3 trial of pirtobrutinib compared to bendamustine plus rituximab in adults with untreated chronic lymphocytic leukaemia/small lymphocytic lymphoma

PETReA: a trial testing whether PET scans can help make treatment decisions for people with follicular lymphoma

P+R-ICE: A phase 2 trial of pembrolizumab with R-ICE chemotherapy in relapsed/refractory diffuse large B-cell lymphoma

XmAb13676: A phase 1 trial of plamotamab in people with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia

ToTem: a phase 1 trial of donor ‘effector memory’ T cells to improve immune system recovery after donor (allogeneic) stem cell transplants

APOLLO+: A data and sample collection study of people with diffuse large B cell lymphoma (DLBCL)

PROSPER: An observational study of Poteligeo in mycosis fungoides or Sezary syndrome

NX-1607: A phase 1 study of NX-1607 in adults with advanced solid tumours

REMIT: A trial looking at radiotherapy as a priming treatment before CAR-T therapy in DLBCL

ZUMA-2: a phase 2 study testing the efficacy of KTE-X19 in people with relapsed/refractory mantle cell lymphoma

NAVAL-1: a phase 2 trial of nanatinostat with valganciclovir in Epstein-Barr Virus-Positive relapsed and refractory lymphomas

OxPLoreD: a study to find out more about pre-cancerous blood conditions

STELLAR: a phase 2 trial of acalabrutinib in people with Richter syndrome

BP43131: A phase 1 study to test the safety and efficacy of RO7443904 in combination with glofitamab in people with relapsed or refractory B-cell non-Hodgkin lymphoma

BO43243: A phase 1 trial of mosunetuzumab in relapsed or refractory chronic lymphocytic leukaemia (CLL)

CO41942: A phase 1/2 trial of moseuntuzumab plus lenalidomide in people with relapsed or refractory follicular lymphoma

CC-95251: A phase 1 trial of a monoclonal antibody in participants with DLBCL or follicular lymphoma

KRT-232: A phase 1b/2 trial of KRT-232 in combination with acalabrutinib in DLBCL or CLL

RAINBOW: a randomised, phase 2/3 trial comparing ibrutinib plus rituximab with standard treatment in people with Waldenström’s macroglobulinaemia

InMIND: A phase 3 study to assess the safety and effectiveness of tafasitamab plus lenalidomide and rituximab with placebo plus lenalidomide and rituximab in people with relapsed or refractory follicular lymphoma or marginal zone lymphoma

NX-5948-301: A phase 1 study of a new treatment called NX-5948 in adults with relapsed or refractory B-cell lymphoma

AZD4573: a phase 2 study of AZD4573 in adults with relapsed or refractory peripheral T-cell lymphoma or classical Hodgkin lymphoma

NVG-111: a phase 1/2 trial of NVG-111 in relapsed or refractory chronic lymphocytic leukaemia, small lymphocytic lymphoma and mantle cell lymphoma

CAPITAL: a phase 2 study of capivasertib in relapsed or refractory B-cell non-Hodgkin lymphoma

CCS1477-02: a phase 1/2a study of CCS1477 in blood cancers, including relapsed or refractory non-Hodgkin lymphoma

NuTide:701: a phase 1 trial to find the best dose and test the safety of a new drug called NUC-7738 in people with advanced solid tumours or lymphoma

REMoDL-A: A phase 2 trial of a targeted drug called acalabrutinib added to standard treatment for people with diffuse large B-cell lymphoma

BRUIN-CLL-321: A phase 3 trial of a targeted treatment called pirtobrutinib in people with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)

BASILICA-A: A study into why anaplastic large cell lymphoma sometimes occurs after breast implants

FLAIR: a randomised phase 3 trial comparing treatments containing ibrutinib with standard first treatment for chronic lymphocytic leukaemia (CLL)

AUTO4 in T-cell lymphoma: a phase 1/2 trial testing AUTO4 CAR-T cells as treatment for people with T-cell lymphoma that has relapsed (come back) or was refractory (didn’t respond) to previous treatment

PROCLIPI: a study aiming to identify factors important in predicting the outcome of cutaneous (skin) lymphomas, mycosis fungoides and Sezary syndrome

SGN35-032: A phase 2 trial of brentuximab vedotin plus chemotherapy in people with peripheral T-cell lymphoma

Improve: The impact of pausing BTKi therapy around COVID 19 vaccination in people with CLL

EPCORE DLBCL-1: A phase 3 trial of epcoritamab in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

PRiZM+: A phase 1 trial of zanubrutinib in people with relapsed or refractory primary central nervous system lymphoma

LOTIS-5: A phase 3 trial of loncastuximab tesirine and rituximab in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

DOLPHIN-VIVO: an observational study looking at diagnosing lymphoma with a less invasive method

CAROUSEL: A phase 1 trial of CAR T-cell therapy in people with relapsed or refractory primary central nervous system (CNS) lymphoma

EPCORE™NHL-1: a phase 1/2 trial of GEN3013 in people with B-cell non-Hodgkin lymphoma that has come back or has not responded to treatment

ECHELON-3: A randomised, phase 3 trial of an antibody treatment called brentuximab vedotin, combined with other targeted treatments, in people with relapsed or refractory diffuse large B-cell lymphoma

JNJ-75348780: A phase 1 trial of a new treatment called JNJ-75348780 in people with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia

BRUIN-MCL-321: A phase 3 trial of a targeted treatment called pirtobrutinib in people with relapsed or refractory mantle cell lymphoma

POLARGO: A phase 3 trial of polatuzumab vedotin, combined with rituximab and chemotherapy, in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

PROACT: A phase 3 trial testing whether a drug called enalapril can prevent heart damage linked to chemotherapy in people with lymphoma or breast cancer

DIRECT: A study looking at genetic changes in diffuse large B-cell lymphoma and other types of high-grade B-cell lymphoma

KEYNOTE 051: a phase 1 / 2 trial aiming to test pembrolizumab in children with a solid tumour (including lymphoma) that has come back or is difficult to treat

EPCORE™ NHL-2: A phase 1b/2 trial of a targeted treatment, epcoritamab, in combination with different chemotherapy regimens, in people with B-cell non-Hodgkin lymphoma

BOOST: studying samples from stem cell transplant donors and recipients to improve transplant success rates and reduce side effects

JNJ-64264681: A phase 1 trial of a new targeted treatment called JNJ-64264681 in people with relapsed or refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia (CLL)

PembroWM: a phase 2 trial of rituximab and pembrolizumab in people with relapsed or refractory Waldenström’s macroglobulinaemia